The effect of rose hip alcoholic extract on the ventricular arrhythmia

Phase 3

Recruiting

• Conditions: Ventricular arrhythmia.; Paroxysmal tachycardia

• Registration Number: IRCT20220516054874N17
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

Age older than 18 years old
Heart failure diagnosis
ICD implantation > 6 months before eligibility test
Signed written informed consent to participate in the study

Exclusion Criteria

New York Heart Association Class IV heart failure
Renal dysfunction with eGFR < 20
Hepatic dysfunction
Body mass index < 18.5 kg/m2
Pregnant or suspected pregnancy
Patients with the following events within 3months before the eligibility test: alteration of antiarrhythmic drug, catheter ablation for ventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization, heart failure requiring hospitalization
Other comorbidities including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer
ICDs unable to record cardiac arrhythmias

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of the ventricular arrhythmias (PVC, NSVT, VT, VF). Timepoint: The beginning of the study and one months later. Method of measurement: ICD (implantable cardioverter-defibrillator) record.

Secondary Outcome Measures

Name	Time	Method
Hospitalization. Timepoint: The beginning of the study and one month later. Method of measurement: Checklist.